DCM
XENE icon

Difesa Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Difesa Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,500
Closed -$884K – 252
2022
Q3 		$884K Buy
+24,500
New +$881K 0.45% 70
2022
Q1 		– Sell
-10,000
Closed -$312K – 259
2021
Q4 		$312K Buy
+10,000
New +$299K 0.21% 100

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Difesa Capital Management's XENE Position: Q4 2022 in Review

Difesa Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q4 2022, closing a stake of 24,500 shares — an estimated $884K sold.

Difesa Capital Management first reported a position in XENE in Q4 2021 and held it in 2 quarters. The position peaked at $884K in Q3 2022. 159 funds tracked by Wall St. Rank hold XENE as of Q4 2022.

  • Difesa Capital Management reported no remaining Xenon Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Difesa Capital Management sold 24,500 Xenon Pharmaceuticals shares in Q4 2022, an estimated $884K.
  • Difesa Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Difesa Capital Management's Xenon Pharmaceuticals position peaked at $884K in Q3 2022.
  • 159 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2022.

Based on Difesa Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.